Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you're weighing up Mounjaro and Wegovy, side effects are probably near the top of your list of concerns. Both are once-weekly injections licensed in the UK for weight management, and both work primarily on gut-hormone pathways that slow digestion and reduce appetite — which means their side-effect profiles overlap considerably. Neither is dramatically easier to tolerate than the other, though small differences in how each medicine acts do show up in the data. As prescription-only medicines, a clinician assesses your individual health picture before any treatment is approved, and that conversation is where the side-effect question really gets answered for you.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Pick up the patient information leaflet for either medicine and the list of possible side effects runs to several pages. That's standard for any medicine, and it reflects every event that was recorded across large clinical trials, however rarely. For most people starting Mounjaro or Wegovy, the day-to-day reality is narrower: gut symptoms dominate. Nausea is the most frequently reported effect for both, followed by loose stools or constipation, burping, reflux and a general feeling of fullness that can shade into queasiness after eating.
These effects are tied to how the medicines work. Slowing gastric emptying is part of the mechanism that reduces appetite, and it's also the reason the stomach complains during the adjustment period. For the majority of people, the worst of it clusters around the first few weeks of each dose step, then settles. Starting at the lowest dose and titrating gradually, as prescribers do, is specifically designed to give your body time to adapt. Our detailed guide to injection side effects covers the full profile of each medicine if you want the granular breakdown before your consultation.
Fatigue, headache and dizziness also appear in the trial data for both medicines, though less consistently than GI effects. Injection-site reactions (mild redness or itching where the pen is used) are generally minor and transient.
Mounjaro (tirzepatide) activates two receptors (GIP as well as GLP-1) while Wegovy (semaglutide) acts on GLP-1 alone. In practice, both mechanisms produce similar GI side-effect patterns, so the dual-agonist design doesn't translate into a cleanly better tolerability story. The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, compared the two medicines head-to-head over 72 weeks and found tirzepatide produced greater average weight reduction, but the study wasn't designed as a tolerability comparison, and neither medicine emerged as clearly easier on the gut.
What does differ is the trajectory of dose increases. Mounjaro is available in six strengths up to 15 mg; Wegovy's standard pathway reaches 2.4 mg weekly, with a higher 7.2 mg dose now approved by the MHRA for eligible patients. A prescriber deciding between them looks at your GI history, any relevant conditions, what other medicines you take, and your weight-related health goals. The overview of UK-licensed weight loss injections explains the licensing basis for both. If you're weighing up your options, our guide to which weight loss injection tends to cause the least side effects looks at how the two medicines compare from a tolerability perspective. The idea that one is categorically gentler than the other isn't well supported by current evidence, individual variation matters far more than the headline comparison.
Mounjaro's dual mechanism does create one practical difference: oral contraceptive absorption may be reduced during the first four weeks of treatment and for four weeks after each dose increase, so women on the pill are advised to add a barrier method during those windows. That's worth discussing with your prescriber before starting.
Most GI symptoms from either medicine are uncomfortable rather than dangerous, and they tend to improve without intervention beyond staying hydrated and eating smaller portions. A few signals, though, need prompt medical attention rather than a wait-and-see approach.
Severe stomach pain that persists and extends through to the back (with or without vomiting) should be assessed urgently. The MHRA highlighted acute pancreatitis as a known, though infrequent, serious risk associated with GLP-1 medicines in a Drug Safety Update issued in January 2026, and that's the symptom pattern to watch for. Similarly, signs of a significant allergic reaction (swelling of the face or throat, difficulty breathing, widespread rash), gallbladder-type pain in the upper right abdomen, or heavy fluid loss from vomiting or diarrhoea that you can't manage with fluids at home all warrant a call to your GP or 111 without delay.
A quick habit that takes under a minute: after each new dose, note the date and your starting symptoms in your phone's notes app. If something escalates, that record helps a clinician assess whether it's dose-timing-related or something that needs investigation. Low mood or thoughts of self-harm are also listed as events to monitor; contact a healthcare professional if these emerge. The NHS patient information for tirzepatide sets out the full list of symptoms to act on for Mounjaro specifically.
The honest answer to 'which injection has fewer side effects' is: it depends on you, and a prescriber is the right person to work through that. Factors that shift the balance include your history with gut conditions, any previous experience of GLP-1 medicines, your current medication list and whether interactions are relevant, and how you feel about the injection process versus a daily tablet (the recently approved oral semaglutide (Wegovy tablets) is a separate option worth knowing about). Our guide to the best weight loss injection for people who are particularly concerned about side effects is a useful starting point if tolerability is your main priority going into a consultation.
At nume, our consultation process puts your answers in front of a GPhC-registered prescriber who reads them the same day, a real clinician, not an automated system. Side effects and tolerability are a normal part of what gets discussed before any prescription is issued. If you'd like to know more about our prescribers and clinical oversight, our clinical team page explains how the service is run. You can also read more about how to access weight loss injections in the UK if you're still in the research stage. And if anything concerns you after starting treatment, our aftercare team is available seven days a week.
For anyone curious about adjacent options, it's worth noting that B12 injections (sometimes marketed alongside weight loss) work through a completely different mechanism and have a distinct side-effect consideration set, covered separately in our B12 injection side effects guide.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.